Skip to main content
Log in

Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

HMN-176, (E)-4-{2-[2-(N-[4-methoxybenzene-sulfonyl]amino)phenyl]ethenyl} pyridine 1-oxide, is a stilbene derivative which inhibits mitosis without significant effect on tubulin polymerization and displays potent cytotoxicity against a variety of human tumor cell lines. The present study evaluated the activity profile of the antineoplastic agent HMN-176 in an ex-vivo soft agar cloning assay (human tumor colony-forming assay) in a panel of 132 human tumor specimens under 14-day continuous exposure at 0.1, 1.0, and 10.0 μg/ml. Thirty percent of specimens in the different treatment groups (39/132 in 0.1 and 1.0 test groups; 40/132 in 10.0 test group) were assessable, falling within the negative and positive control parameters. At these dose levels, responses were observed in 32% (11/34), 62% (21/34), and 71% (25/35) of assessable specimens, respectively. HMN-176 demonstrated activity towards 75% of the breast cancer specimens (6/8) treated with 1.0 μg/ml, 67% of non small-cell lung (4/6) and 57% of ovarian (4/7) cancer specimens treated with 10 μg/ml. Low levels of cross-resistance to cisplatin, cyclophosphamide, 5-fluorouracil, and etoposide were also observed. There was a positive relationship between HMN-176 concentration and effect, demonstrating greatest overall activity at 10.0 μg/ml. Evaluation of differential gene expression in drug-sensitive (A2780) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 μg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene (TIMP) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance. In conclusion, in vitro responses demonstrate efficacy at pharmacologically relevant concentrations, which suggests that HMN-176 deserves further evaluation in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Takagi M, Honmura T, Watanabe S, Yamaguchi R, Nogawa M, Nishimura I, Katoh F, Matsuda M, Hidaka H: In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs 21(4): 387-399, 2003

    Google Scholar 

  2. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H: HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug resistant cells by targeting the transcription factor NF-Y. Cancer Res. 63(20): 6942-6947, 2003

    Google Scholar 

  3. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977.

    Google Scholar 

  4. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R: Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70: 1027-1041, 1981

    Google Scholar 

  5. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, Von Hoff DD: Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 70: 1379-1382, 1986

    Google Scholar 

  6. Hanauske U, Hanauske A-R, Marshall MH, Muggia VA, Von Hoff DD: Biphasic effects of vanadium salts on in vitro tumor colony growth. Int J Cell Cloning 5: 171-178, 1987

    Google Scholar 

  7. Von Hoff DD, Clark GM, Stogdill BJ, Sarodsy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AP, Sandbach JF: Prospective clinical trial of a human tumor cloning system. Cancer Res 43: 1926-1931, 1983

    Google Scholar 

  8. Shoemaker RH, Wolpert-Defillipes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, Von Hoff DD: Application of a human tumor colony forming assay to new drug screening. Cancer Res 45: 2145-2153, 1985

    Google Scholar 

  9. Browman GP, Levine MN, Robert RS: Editorial: Bench to bedside research and the human tumor stem-cell assay-bridging the credibility gap. J Clin Oncol 4: 1730-1731, 1986

    Google Scholar 

  10. Von Hoff DD: Human tumor stem cell assays. Int J Cell Cloning 5: 365-367, 1987

    Google Scholar 

  11. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD: Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 3: 121-124, 1992

    Google Scholar 

  12. Eckardt JR, Burris III HA, Kuhn JG, Bissery MC, Klink-Alakl M, Clark GM, Von Hoff DD: Activity of intoplicine (RP60475), a new DNAtopoisomerase I and II inhibitor, against human tumor colonyforming units in vitro. J Natl Cancer Inst 86 (1): 30-33, 1994

    Google Scholar 

  13. Raymond E, Hanauske A, Faivre S, Izbicka E, Clark G, Rowinsky EK, Von Hoff DD: Effects of prolonged versus short-term exposure paclitaxel (TaxolR )onhuman tumor colony-forming units. Anti-Cancer Drugs 8: 379-385, 1997

    Google Scholar 

  14. Hidalgo M, Izbicka E, Cerna C, Gomez L, Rowinsky EK, Weitman SD, Von Hoff DD: Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay. Anti-Cancer Drugs 10(3): 295-302, 1999

    Google Scholar 

  15. Diab SG, Hilsenbeck SG, Izbicka E, Weitman SD, Von Hoff DD: Significant activity of a novel cytotoxic agent, Ly295501, against a wide range of tumors in the human tumor cloning system. Anti-Cancer Drugs 10: 303-307, 1999

    Google Scholar 

  16. Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman SD, Von Hoff DD: Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann Oncol 10: 449-453, 1999

    Google Scholar 

  17. Sakata K, Shigemasa K, Nagai N, Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17(4): 673-681, 2000

    Google Scholar 

  18. Von Hoff, Daniel D: He's Not Going to Talk About In vitro Predictive Assays Again, Is He? JNCI 82(2): 96-101, 1990

    Google Scholar 

  19. Li YT, Shen F, Bai JY, Cheng GF: Inhibition of dexamethasone, indomethacin and resveratrol on matrix metalloproteinase-9 and the mechanism of inhibition. Yao Xue Xue Bao 38(7): 501-504, 2003

    Google Scholar 

  20. Liang Y, McDonnell S, Clynes M. Examining the relationship between cancer invasion/metastasis and drug resistance. Curr Cancer Drug Targets 2(3): 257-277, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Medina-Gundrum, L., Cerna, C., Gomez, L. et al. Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression. Invest New Drugs 23, 3–9 (2005). https://doi.org/10.1023/B:DRUG.0000047100.64540.f6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000047100.64540.f6

Navigation